DOAJ (DOAJ: Directory of Open Access Journals) · 2022 · 90 citations · 26 references
Open access
MedicineNeurosciencePharmacologyAnesthesiaMolecular PharmacologyNeuropharmacologyAcute Ischemic StrokeGabaergic PharmacologyNeuroprotectionNeuroprotective PharmacologyStrokeStroke PharmacotherapyCerebral InjuryCerebral Ischemia NeuroprotectionCerebral Ischemia PharmacotherapyCerebral Ischemia Reperfusion InjuryCerebral ReperfusionNeurological DysfunctionNeurological FunctionRodent Cerebral Ischemia
Min Shi,* Jing Chen,* Tianxiao Liu,* Weixin Dai, Zhan Zhou, Lifei Chen, Yubo Xie Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, Nanning, 530021, Peopleâs Republic of China*These authors contributed equally to this workCorrespondence: Yubo Xie, Department of Anesthesiology, The First Affiliated Hospital of Guangxi Medical University, No. 6 Shuang-yong Road, Nanning, 530021, Peopleâs Republic of China, Tel +86 186 7795 8208, Email xybdoctor@163.comIntroduction: Remimazolam is a novel benzodiazepine γ-aminobutyric acid A (GABAa) receptor agonist used for sedation and the induction as well as maintenance of general anesthesia. Previous research proved that anesthetic agents acting on GABAa receptor, such as thiopentone, propofol and midazolam, have protective actions for cerebral ischemia/reperfusion (I/R) injury. We here probed into remimazolam for its protective effect and potential mechanism of action against cerebral I/R injury.Material and Methods: A rat model of middle cerebral artery occlusion (MCAO) with focal transient cerebral I/R injury was established and was given tail vein injection of gradient remimazolam (5, 10, 20 mg/kg) after 2 h of ischemia. Following 24 h of reperfusion, neurological function, brain infarct volume, morphology of cerebral cortical neurons, and expressions of corticocerebral NLRP3, ASC, caspase-1, GSDMD, IL-1β and IL-18 were evaluated.Results: The results showed that remimazolam could effectively improve the neurological dysfunction, reduce the infarct volume and alleviate the damage of cortical neurons after I/R injury. Notably, the expression of NLRP3 inflammasome pathway was down-regulated, suggesting that remimazolam exerted protective actions on I/R injury by suppressing pyroptosis with decreased expression and release of inflammatory factors, and the involvement of the NLRP3 inflammasome pathway might be the core during that process. Overall, our results indicate that NLRP3 inflammation is a promising target.Conclusion: Based on this mechanism, remimazolam may be one of the ideal anesthetic drugs for patients with ischemic stroke.Keywords: remimazolam, NLRP3 inflammasome, ischemia/reperfusion injury, I/R, pyroptosis, inflammation
26
Reversible middle cerebral artery occlusion without craniectomy in rats.
Enrique Zea Longa, Philip R. Weinstein, Shaun W. Carlson et al. · Stroke · 1989 · 7.5K citations · Full text
Medicine, Neuroscience, Surgery +17
Mohsen Naghavi, Amanuel Alemu Abajobir, Cristiana Abbafati et al. · The Lancet · 2017 · 4.9K citations · Full text
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Xing Liu, Zhibin Zhang, Jianbin Ruan et al. · Nature · 2016 · 3.2K citations · Full text
FDA-approved disulfiram inhibits pyroptosis by blocking gasdermin D pore formation
Jun Hu, Xing Liu, Shiyu Xia et al. · Nature Immunology · 2020 · 1.1K citations · Full text
Lieselotte Vande Walle, Mohamed Lamkanfi · Current Biology · 2016 · 633 citations · Full text